首页> 外文OA文献 >Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers
【2h】

Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers

机译:急性髓性白血病在艾滋病毒感染的患者中:几个问题,答案较少

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Both human immunodeficiency virus (HIV) infection and acute myeloid leukemia (AML) may be considered relatively uncommon disorders in the general population, but the precise incidence of AML in people living with HIV infection (PLWH) is uncertain. However, life expectancy of newly infected HIV-positive patients receiving anti-retroviral therapy (ART) is gradually increasing, rivaling that of age-matched HIV-negative individuals, so that the occurrence of AML is also expected to progressively increase. Even if HIV is not reported to be directly mutagenic, several indirect leukemogenic mechanisms, mainly based on bone marrow microenvironment disruption, have been proposed. Despite a well-controlled HIV infection under ART should no longer be considered per se a contraindication to intensive chemotherapeutic approaches, including allogeneic hematopoietic stem cell transplantation, in selected fit patients with AML, survival outcomes are still generally unsatisfactory. We discussed several controversial issues about pathogenesis and clinical management of AML in PLWH, but few evidence-based answers may currently be provided, due to the limited number of cases reported in the literature, mainly as case reports or small retrospective case series. Prospective multicenter clinical trials are warranted to more precisely investigate epidemiology and cytogenetic/molecular features of AML in PLWH, but also to standardize and further improve its therapeutic management.
机译:人类免疫缺陷病毒(HIV)感染和急性髓性白血病(AML)都可能被认为是一般人群中的相对罕见的疾病,但AML与艾滋病毒感染(PLWH)的人的精确发病率是不确定的。然而,新感染的艾滋病毒治疗患者的预期寿命逐渐增加,依赖于年龄匹配的HIV阴性个体,使AML的发生也预期逐渐增加。即使没有报道艾滋病毒直接诱变,已经提出了几种间接白血病机制,主要是基于骨髓微环境中断的。尽管艺术良好控制的艾滋病毒感染,但应不再被认为本身对强化化学治疗方法的禁忌症,包括同种异体造血干细胞移植,在所选择的AML患者中,存活结果仍然不令人满意。我们讨论了PLWH中AML发病机制和临床管理的几个有争议的问题,但目前可能提供了很少的证据答案,因为文献中报告的有限案件,主要是案例报告或小型回顾性案例系列。前瞻性多中心临床试验有必要更精确地研究PLWH中AML的流行病学和细胞遗传学/分子特征,而且还用于标准化和进一步改善其治疗管理。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号